Developer of software applications designed to deliver the precision cancer care for every cancer patient through precision medicine. The company's software integrates previously fragmented clinical, molecular, treatment, and health outcomes data and delivers it to physicians at the point of care, enabling oncologists to deliver personalized care to every patient who needs it.
Generating Revenue
Privately Held (backing)
Venture Capital-Backed
The company raised $30 million of Series D venture funding from Ascension Ventures, GE Ventures and Healthbox on November 14, 2017, putting the company's pre-money valuation at $90 million. Safeguard Scientifics, Social Capital, Amgen Ventures, Medidata Solutions, Merck & Co. and Roche Venture Fund also participated in the round. The funds will be used to expand operations and bring precision oncology to more healthcare providers and improve patient care.
Add a review